珠海都市网
您当前的位置 :首页 > 文传商讯 > 正文
Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases
2020年07月08日 17:32:37来源:作者:

The collaboration with Numab Therapeutics expands Boehringer Ingelheim’s bi- and multi-specific antibody pipeline with two front-runner projects in lung and gastrointestinal (GI) cancer and geographic atrophy (GA)
Numab’s proprietary platform enables the engineering of first-in-class and best-in-class bi- and multi-specific antibodies in a true plug-and-play fashion

INGELHEIM, Germany & WAEDENSWIL, Switzerland--(BUSINESS WIRE)--Boehringer Ingelheim and Numab Therapeutics (Numab) today announced that they have entered into a research collaboration and worldwide licensing agreement. It will start with two projects aiming at novel therapies for difficult-to-treat lung and gastrointestinal (GI) cancers and patients with geographic atrophy (GA), a progressive, irreversible retinal disease that occurs in patients with age-related macular degeneration (AMD) for which there is no current treatment. The collaboration brings together Boehringer Ingelheim’s leading expertise in the research and development of life changing breakthrough therapies with Numab’s multi-specific antibody platform.

Lung and GI cancers and retinal diseases are key focus areas of Boehringer Ingelheim’s research and development program. In oncology the company has built a broad and diverse pipeline, combining cancer immunology and cancer cell directed approaches. The novel T-cell engager to be developed with Numab adds to Boehringer Ingelheim’s growing cancer immunology portfolio and supports the strategy to take cancer on by targeting ‘cold’ tumors with synergistic combination approaches. In retinal diseases Boehringer Ingelheim is pursuing a holistic approach leveraging existing expertise in oncology, inflammation, neurodegeneration, fibrosis and cardiometabolic diseases. The new GA program with Numab further broadens the company’s comprehensive portfolio of next generation retinal therapy approaches in various stages of development up to Phase 2 in macular degeneration and diabetic retinal diseases.

“We are thrilled to work with the excellent team at Numab to advance our portfolio assets. Numab’s technology platform fits well with our internal antibody discovery and engineering capabilities and will enhance our efforts to deliver transformative antibody-based therapeutics to patients,” said Paige Mahaney, SVP and US Discovery Research Site Head at Boehringer Ingelheim.

“We are looking forward to working with Boehringer Ingelheim, a global leader in pharmaceutical R&D with profound expertise across a broad spectrum of therapeutic areas, further validating our technology platform. This addition to our growing roster of partnerships represents another key milestone in our business development efforts,” commented Dr. Oliver Middendorp, Chief Business Officer of Numab Therapeutics. “The upfront payment and near-term milestones attached to this alliance will further strengthen Numab’s ability to accelerate the development of key proprietary assets.”

Under the terms of the alliance, the partners will work together to discover one novel multi-specific antibody drug candidate in each area. Boehringer Ingelheim receives from Numab an exclusive worldwide license to develop and commercialize the resulting candidates in exchange for upfront and milestone payments, as well as tiered royalties on net sales of all products resulting from the alliance.

With today’s announcement, Numab has been able to secure seven ongoing relationships with leading pharmaceutical companies including 3SBio / Sunshine Guojian, Boehringer Ingelheim, Eisai Co., Ltd., CStone Pharmaceuticals, Ono Pharmaceutical Co., Ltd., Kaken Pharmaceutical Co., Ltd., and Tillotts Pharma AG.

Please click on the following link for ‘Notes to Editors’:

http://www.boehringer-ingelheim.com/press-release/numab

责任编辑: admin

看新闻,关注新闻

淘宝网友:大把大把的钱
评论:有没有一个女生会对我这样说:“别装了,我知道你喜欢我”

凤凰网友:凝固旳悲伤※
评论:长大成人这件事最恐怖的地方之一,在于,你或许会变成自己曾经最看不起的那种人。

腾讯网友:岁月静好moon
评论:八戒,别以为你站在路灯下就是夜明猪了

搜狐网友:没你妈娇柔 -   
评论:做一个单纯的人,走一段幸福的路。

天猫网友:颠覆 wounded
评论:做女孩一定要经的起谎言,爱的起敷衍,忍的了欺骗,忘得了诺言,放的下一切,最后用笑来伪装你的泪眼!

百度网友:那痛撕心裂肺
评论:生活之所以有回忆,不是因为突然想起,而是因为不能忘记!

网易网友:你真叫我作呕
评论:我的优点是:我很淑女;但是我的缺点是:我淑女的不明显。

天涯网友:摆摊卖青春
评论:我来到我们来过的小路,捡起我们可耻的幸福。

猫扑网友:忘記飛の蝶
评论:想让一个人对你念念不忘的话,最好的办法就是向他借钱。

本网网友:目光瞄准 Follow
评论:> 我说:要有上班以外的生活!于是,老婆告诉我这个可以有、于是:我有了加班!

相关阅读
分享到:
版权和免责申明

珠海都市网所有文字、图片、视频、音频等资料均来自互联网,不代表本站赞同其观点,本站亦不为其版权负责。相关作品的原创性、文中陈述文字以及内容数据庞杂本站无法一一核实,如果您发现本网站上有侵犯您的合法权益的内容,请联系我们,本网站将立即予以删除!

焦点新闻